Notes on Bacteria, Antibiotics, and Antibiotic Resistance

Bacteria: Ubiquity and Role in Life on Earth

Microorganisms called bacteria were some of the first life forms to appear on Earth.
They consist of a single cell (unicellular organisms).
Their total biomass is greater than that of all plants and animals combined.
They live virtually everywhere: on the ground, in the water, on your kitchen table, on your skin, even inside you.
There are roughly 10 times more bacterial cells inside you than your body has human cells; many of these bacteria are harmless or even beneficial, helping digestion and immunity.
However, there are a few bad apples that can cause harmful infections, ranging from minor inconveniences to deadly epidemics.
Despite their small size, bacteria have a huge impact on health, ecosystems, and medicine.

Antibiotics are medicines designed to fight bacterial infections.
They can be synthesized from chemicals or occur naturally in things like mold.
They kill or neutralize bacteria by interrupting cell wall synthesis or interfering with vital processes like protein synthesis.
They can target bacterial processes while leaving human cells unharmed, enabling selective toxicity.
The deployment of antibiotics during the 20th century rendered many previously dangerous diseases easily treatable.
This revolution dramatically lowered mortality from bacterial infections and reshaped medicine, surgery, and public health.

The problem arises due to natural selection acting on random mutations in bacteria.
Individual bacteria can undergo random mutations; most are harmful or neutral, but occasionally a mutation provides a survival advantage under antibiotic pressure.
A mutation that confers resistance to a specific antibiotic gives its bearer an edge when that antibiotic is present.
In antibiotic-rich environments (e.g., hospitals), nonresistant bacteria are killed off, creating space and resources for resistant ones to thrive.
Resistant bacteria propagate by reproduction and by transferring resistance genes to others.
Gene transfer mechanisms include:
- Releasing DNA upon death, which can be picked up by other bacteria (transformation).
- Conjugation, where bacteria connect through pili (pilae) to share genes.
Over time, resistant genes proliferate, creating entire strains of resistant "superbacteria".

Resistance spreads as mutated genes proliferate, producing resistant strains.
Conjugation via pili (pilae) enables horizontal transfer of resistance genes between bacteria.
DNA released from dead bacteria can be taken up by neighbors, spreading resistance.
These processes increase the genetic diversity of resistance in bacterial communities and accelerate the emergence of multi-drug resistant organisms.

MRSA: Staphylococcus aureus that has developed resistance to beta-lactam antibiotics like penicillin, methicillin, and oxacillin.
Resistance mechanism (as described in the transcript): due to a gene a that replaces the protein beta-lactams normally target and bind to, allowing the bacteria to continue building cell walls unimpeded.
Salmonella: can produce enzymes like beta-lactamases that break down beta-lactam antibiotics before they can exert their effect.
Escherichia coli (E. coli): a diverse group; some strains can prevent the function of antibiotics like quinolones by actively pumping inhibitors that enter the cell back out (efflux) or by preventing entry.
The existence of such strains demonstrates how resistance can undermine standard treatments and complicate infections.

The World Health Organization has made developing novel treatments a priority due to the rise of resistant bacteria.
Scientists are exploring alternative strategies, such as phage therapy, which uses bacteriophages to target specific bacteria, and vaccines to prevent infections.
The goal is to expand the toolkit beyond traditional antibiotics and to stay ahead of evolving bacterial defenses.

Curbing excessive and unnecessary use of antibiotics is crucial (e.g., avoiding antibiotics for minor infections that can resolve on their own).
Changing medical practice to prevent hospital infections can reduce opportunities for resistance to develop and spread.
De-escalation strategies—using narrower-spectrum antibiotics when appropriate—can reduce selective pressure and help preserve antibiotic effectiveness.
The broader implications include ethical and practical considerations: stewardship, access to treatments, costs, and the need for prevention (vaccines, infection control).
The overall message is that in the war against superbugs, reducing misuse and focusing on prevention may sometimes be more effective than an endless arms race.

Darwinian natural selection underpins antibiotic resistance; random mutation plus selective pressure shapes bacterial populations.
Horizontal gene transfer accelerates spread of resistance across species and strains, making containment more challenging.
The microbiome context matters: many bacteria are beneficial, so stewardship aims to preserve beneficial microbes while eliminating pathogens.
Real-world relevance includes clinical decision-making, hospital infection control, public health policy, and global health security.
Ethical considerations include balancing patient access to effective treatments with prudent use to preserve their effectiveness for future patients.

There are roughly 10 times more bacterial cells in the human body than human cells.
Antibiotics work by targeting bacterial features (cell wall synthesis, protein synthesis) while sparing human cells.
Resistance emerges via mutations and horizontal gene transfer (transformation, conjugation via pili).
MRSA is an example of beta-lactam resistance in Staphylococcus aureus; Salmonella can produce beta-lactamases; E. coli can use efflux mechanisms against quinolones.
New strategies (phage therapy, vaccines) and stewardship are essential to manage resistance and protect public health.